GHPC Executive Summary:

 GHPC Mission Statement:                “To Bring Health to Life”

Global Health Partnership, LLC (GHPC) has developed marketing strategies and worldwide sales for its two flagship nutraceutical products, “Myogence” and “Atheromine” as well as other products and services. These two initial products can dramatically enhance nutrition and optimal cellular performance either in a solid capsule or liquid oral form or by liquid infusion through an intravenous (IV) catheter. These novel and revolutionary products were specifically designed and developed to treat and/or reverse the effects of two of the greatest health threats in the world today. Nutritional inadequacies are associated with heart and cardiovascular diseases in the developed world and with serious diseases like HIV/AIDS in the developing world. GHPC’s products are poised to address both of these highly lethal problems.

1.) Coronary Heart Disease and Cardiovascular Diseases (CHD/CVD) can be treated today with “Atheromine” better than with any other products on the market. Atheromine lowers total cholesterol levels in the blood, improving the LDL/HDL (“bad cholesterol/good cholesterol”) ratio, thus arresting and/or reversing plaque in artery walls. Furthermore, it increases blood flow to vital tissues previously compromised by atherosclerosis, and enhances natural or native immunity and defense mechanisms, thus preventing and reversing the principal cause of heart attacks and death.

2.) “Poor Nutrition” describes many forms of bodily starvation. In most healthy people, poor nutrition is an imbalance between the requirements for optimal cellular performance and the actual quality and quantity of food ingested, digested and delivered to the body’s tissues and organs. In optimizing energy, strength, power, endurance, overall health, well being, activity and productivity, Myogence is a nutritional supplement to prudent diets, exercise programs and/or the usual activities of daily living. This product is not just for elite athletes, but for anyone who strives to achieve the highest levels of human performance, longevity and quality of life ranging from youth to geriatric age groups.

GHPC’s business model is built on in-house research, expert scientific laboratory testing, independent clinical trials, marketing, sales, and new digital information and supply chain management systems. These products were invented and developed by one of the world’s leading physicians and surgeons, Stanley J. Dudrick, MD. He is a pioneer of the techniques of “intravenous” hyperalimentation (IVH) and total parenteral nutrition (TPN), discoveries that are routinely used in hospitals, operating rooms, critical care units, clinics and homes around the world every day. Dr. Dudrick’s medical discoveries, innovations, inventions and products have saved, and continue to save, millions of lives while fostering a continuing revolution in healthcare delivery worldwide. Moreover, his work has also stimulated the early development of the multi-billion dollar nutritional market.

GHPC will take existing, proven products to global markets. The products are manufactured using world-class methods “made in America.” In addition to immediate penetration in North American, European and Far Eastern markets, GHPC will design and produce products for special demographic and humanitarian applications under rigorous, independent, clinical trials worldwide. These scientific techniques have evolved from the professional academic, clinical and scientific team led by Dr. Dudrick.

With its professional management team, GHPC will sell the products directly to clients through well-established distribution channels. One important targeted group is the over 35 million people worldwide with HIV/AIDS requiring Anti-Retroviral Treatment (ART). Myogence will relieve harsh, adverse reactions and acute toxic side effects related to this regime. Utilizing Clinical Trials in Uganda, where the disease was discovered in the early 1980’s, GHPC intends to prove this scientifically. Two senior Members of GHPC’s Management and one Scientific Board member have built decades of indigenous alliances and successful experience with top Government and Health leaders in these markets. More importantly, the company is on excellent terms with the leadership of the world’s two major global funding institutions (Global Fund in Geneva and PEPFAR in Washington DC) that will finance the company’s products for these markets. Over $50 billion in Funds are available over the next 5 years from which to purchase GHPC’s products and services.

GHPC will prove that its products are highly effective and non-toxic in fighting the debilitating effects of various diseases including tuberculosis, malaria, and other infectious diseases caused by bacteria, fungi, viruses and parasites. Many existing Pharmaceutical treatment regimens have serious side effects that often impinge on or interrupt vital nutritional and metabolic processes. Crucial factors such as compliance and adherence as well as the bio-availability of treatments themselves become compromised as malnutrition increases. Patient outcomes then worsen in mutually reinforcing ways while leading to additional complications, increased morbidity and, most often, to death.

Because the problem is common to both wealthy and poor alike, there is a growing and urgent demand by the public, clinicians and governments for scientifically valid relief and solutions. The underlying delivery technology inspired by Dr. Dudrick’s research holds promise for numerous configurations. These are based on the unique nutritional requirements of different disease states and demographic profiles. GHPC’s product array can meet this demand, grow steadily and thus enable a long-term leadership position in the future development of these very useful treatments, varying from general to highly specific formulations.

GHPC will immediately generate revenue streams with sales of market-ready products. In addition, clinical trials will be undertaken on new adaptations of these products already identified to fill an existing global demand for GHPC’s technologies. Many products will continue to advance through the development pipeline for the foreseeable future. In order to stay ahead of any encroaching predators or competition, GHPC will continuously update and improve its products, such as natural derivatives of the two mainstream products. GHPC can easily produce additional novel and scientifically-endorsed technologies that will evolve at an increasing rate from market experience.

n the design, manufacture and delivery of existing and new products, as well as the acquisition of new technologies, GHPC principals have always pursued, and will continue to pursue, the highest standards of conscientious patient care, advancement of medical science and achievement of the best possible clinical results. By targeting and effecting optimal cellular performance, GHPC will break new and profitable ground in addressing health problems at the core, metabolic level. As GHPC grows and generates substantial revenues, it will build its own in-house laboratories to test immunocompetence, variable organ function, and total body composition and wellness as part of our overall mission.

THE MARKET AND OPPORTUNITY:

In spite of annual U.S. sales in excess of $50 Billion and an annual global market in excess of $300 Billion, the Preventative/ Restorative market place is extremely fragmented. It is dominated largely by products that rely on questionable and controversial ingredients (sugar, caffeine, anabolic steroids, vitamins and/or herbs alone). These result in limited short-term gratification and are often followed by a period of “let down”. Demand for performance enhancement, in addition to increasing longevity and nutritional advantage has outstripped the pace of scientific and regulatory validation. GHPC is poised to be the leading entity to establish a trusted global consumer brand in this field. Few other companies will be able to match our scientific validation process.